P/E ratio for Spectrum Pharmaceuticals (SPPI)

P/E ratio history for Spectrum Pharmaceuticals from 2001 to 2023

PE ratio at the end of each year

P/E ratio for similar companies or competitors

Company	P/E ratio	P/E ratio differencediff.	Country
Teva Pharmaceutical Industries TEVA	-11.0	286.04%	🇮🇱 Israel
Seagen SGEN	-57.0	1,893.72%	🇺🇸 USA
Curis CRIS	-0.3080	-89.23%	🇺🇸 USA
Biogen BIIB	7.93	-377.32%	🇺🇸 USA
Bristol-Myers Squibb BMY	14.4	-604.73%	🇺🇸 USA
Abbott Laboratories ABT	38.4	-1,443.28%	🇺🇸 USA
Novartis NVS	26.0	-1,007.52%	🇨🇭 Switzerland
Johnson & Johnson JNJ	10.3	-458.49%	🇺🇸 USA
Pfizer PFE	14.2	-595.33%	🇺🇸 USA
GlaxoSmithKline GSK	9.60	-435.47%	🇬🇧 UK

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.